Not Signed In -
Levalbuterol |
levalbuterol HCl; Xopenex |
Xopenex®-HFA inhaler. Levalbuterol (Xopenex®) is the R-enantiomer of the short-acting β2-adrenergic receptor agonist albuterol. As a bronchodilator, it is used to treat asthma and COPD. In general, levalbuterol has similar effects, pharmacokinetics, and pharmacodynamics to albuterol. However, its manufacturer, Sepracor, has implied (although not directly claimed) that the presence of only the R-enantiomer produces fewer side-effects. Physicians sometimes elect to use levalbuterol in ...
Wikipedia - [full article]
Levalbuterol Clinical Trials
- A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation
ClinicalTrials.gov Identifier: NCT00583778 - Recruiting
Asthma
- Continuous Levalbuterol for Treatment of Status Asthmaticus in Children
ClinicalTrials.gov Identifier: NCT00124176 - Completed
Asthma
- Study of Daily Dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects with Asthma
ClinicalTrials.gov Identifier: NCT00073814 - Completed
Asthma
- Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older with Asthma
ClinicalTrials.gov Identifier: NCT00073827 - Completed
Asthma
- Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older with Asthma
ClinicalTrials.gov Identifier: NCT00073840 - Completed
Asthma
- Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older with Asthma
ClinicalTrials.gov Identifier: NCT00064389 - Completed
Asthma
- Evaluation of the Effect of Levalbuterol on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma
ClinicalTrials.gov Identifier: NCT00320034 - Recruiting
Asthma
- Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol
ClinicalTrials.gov Identifier: NCT00325767 - Completed
Mucociliary Clearance
- Efficacy Study of Single-Dose Levalbuterol Tartrate Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI) Versus Placebo in Prevention of Exercise-Induced Bronchospasm (EIB) in Subjects 18 Years of Age and Older With Exercise-Induced Bronchospasm
ClinicalTrials.gov Identifier: NCT00268723 - Completed
Exercise-Induced Bronchospasm
Resources
- Levalbuterol (Drug Digest)
- Xopenex (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
